Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients' analysis.
about
Rituximab for treating inhibitors in people with inherited severe hemophiliaRituximab for treating inhibitors in children with hemophiliaThe anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia AEradication of factor VIII inhibitors in patients with mild and moderate hemophilia AInhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practiceMild hemophilia A.Cytokine-conditioned dendritic cells induce humoral tolerance to protein therapy in mice.Key issues in inhibitor management in patients with haemophilia.Predictors of quality of life among adolescents and young adults with a bleeding disorderImmune tolerance induction in haemophilia: evidence and the way forward.Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice.The reversal of inhibitors in congenital hemophilia.Factor VIII inhibitors in hemophilia A: rationale and latest evidenceInhibitor eradication with rituximab in haemophilia: where do we stand?Inhibitors - genetic and environmental factors.Immunosuppressive agents in the treatment of inhibitors in congenital haemophilia A and B--a systematic literature review.ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective.US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors.Rituximab for treating inhibitors in people with inherited severe hemophilia.Rituximab for the treatment of high titre inhibitors in mild haemophilia A.Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor.Bortezomib delays the onset of factor VIII inhibitors in experimental hemophilia A, but fails to eliminate established anti-factor VIII IgG-producing cells.Rituximab as first-line treatment for the management of adult patients with non-severe hemophilia A and inhibitors.Successful eradication of inhibitor of late recurrence and other high risk prognostic factors in a patient with severe haemophilia A.Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII-specific T cells.Factor VIII inhibitory antibody in a patient with combined factor V/factor VIII deficiency.Identical but different: haemophilia B in monozygotic twins with inhibitor in one brother and subsequent successful immune tolerance induction.Late immune tolerance induction in an adult with severe haemophilia A and high-responder inhibitor: 1-year outcome.How I manage patients with inherited haemophilia A and B and factor inhibitors.Rituximab for treatment of inhibitors in haemophilia A. A Phase II study.
P2860
Q24186623-C58303D5-65CB-4FF1-AE73-DDFEB12A97D5Q24197700-96186155-C0B8-4B67-88E6-68904455F24AQ26778199-AF6FDE0F-B82F-4965-AF5D-285206CBBDEEQ30539581-1C38BE92-F866-4425-8C8A-6F250F0D905DQ34157402-74C82959-FBF5-4F86-8695-017E100DD1BAQ34614695-2E39FE27-DBB1-4D2A-9ADE-7D7133A72980Q36114240-CB910817-9F89-4790-A4BF-79F37EBE34C3Q37602415-CA5041B2-3BD2-406B-8ECC-DF1CB6FF932DQ37740965-9B61F74F-D244-4E09-9464-E92F59EA8505Q37903944-FE5CA139-0A24-4D3F-B153-0B646B078106Q37977140-8B6CD170-958D-4A7F-84A5-DDD1E090BF24Q38077139-87789FB3-1D23-406E-A1F9-5B38BB111E9CQ38101041-1DB83965-5B88-44BC-81A3-B8B44C2447D3Q38195908-BEC2480B-8F51-40ED-97AF-08DDAB60FD35Q38206856-510751C2-8EF9-4B9E-BDD2-FC9EAA391B66Q38222574-B90E1DC4-15B5-459B-AE2D-C40FBB5DCDE3Q38224296-CDAF964E-2E37-4684-83A3-3DAE482356B5Q38511360-38ED22F1-2CBA-4E05-9284-A5CE04DEE686Q38661525-3E40C298-BC5F-4D2F-B0A2-38AC94045816Q42430805-BF2C4CED-8414-425B-983F-6D78A57C8824Q43007265-B238B2AA-D11B-4B8C-8803-5A2D2BCA6BACQ44236379-C82B855B-69F2-4862-B52F-89D9187D09C0Q45863855-1A2C4E20-3B31-4286-B96A-B15633CF8090Q45870476-231601B6-0817-4A0A-80D0-96ED38C47E38Q45870677-E9276129-CA08-44F1-AAB2-896EC680ACE9Q45870991-FE226414-4E0B-4E6F-868A-C639BA33F61CQ45879318-B5D0D234-4AF9-419E-BF05-DBA0D71F0A0CQ45880271-6E4B7669-B9B3-4852-A337-C8BE5BDEA64BQ48359988-17D839E7-B5C6-43B8-83C0-BBEA299C23A8Q49866575-6F37CAF9-68F1-40BD-979E-D4CCADBDBF41
P2860
Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients' analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immune tolerance with rituxima ...... individual patients' analysis.
@en
Immune tolerance with rituxima ...... individual patients' analysis.
@nl
type
label
Immune tolerance with rituxima ...... individual patients' analysis.
@en
Immune tolerance with rituxima ...... individual patients' analysis.
@nl
prefLabel
Immune tolerance with rituxima ...... individual patients' analysis.
@en
Immune tolerance with rituxima ...... individual patients' analysis.
@nl
P2093
P921
P1433
P1476
Immune tolerance with rituxima ...... individual patients' analysis.
@en
P2093
G L Salvagno
M Cruciani
M Franchini
M Montagnana
M Zaffanello
P304
P356
10.1111/J.1365-2516.2008.01839.X
P577
2008-07-28T00:00:00Z